Abbott Laboratories (ABT): Price and Financial Metrics
Abbott Laboratories (ABT)
Today's Latest Price: $92.23 USD
Updated Jul 2 7:00pm
Add ABT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABT Stock Summary
- Abbott Laboratories's market capitalization of $161,725,528,156 is ahead of 99.13% of US-listed equities.
- Abbott Laboratories's stock had its IPO on January 1, 1986, making it an older stock than 92.91% of US equities in our set.
- In terms of volatility of its share price, ABT is more volatile than only 1.7% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Abbott Laboratories are NVO, TMO, SAP, NKE, and ORCL.
- ABT's SEC filings can be seen here. And to visit Abbott Laboratories's official web site, go to www.abbott.com.
ABT Stock Price Chart Technical Analysis Charts
ABT Price/Volume Stats
| Current price | $92.23 | 52-week high | $100.00 |
| Prev. close | $91.64 | 52-week low | $61.61 |
| Day low | $91.93 | Volume | 3,845,629 |
| Day high | $93.06 | Avg. volume | 8,351,287 |
| 50-day MA | $91.23 | Dividend yield | 1.56% |
| 200-day MA | $85.79 | Market Cap | 163.14B |
Abbott Laboratories (ABT) Company Bio
Abbott Laboratories manufactures and sells health care products worldwide. The company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company was founded in 1888 and is based in Abbott Park, Illinois.
ABT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $92.23 | $39.96 | -55% |
Below please find a table outlining a discounted cash flow forecast for ABT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Abbott Laboratories ranked in the 29th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Abbott Laboratories ended up being:
- As a business, ABT is generating more cash flow than 91.53% of positive cash flow stocks in the Healthcare.
- The business' balance sheet suggests that 10% of the company's capital is sourced from debt; this is greater than merely 21.87% of the free cash flow producing stocks we're observing.
- ABT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 40.63% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -56% |
| 1% | -55% |
| 2% | -55% |
| 3% | -55% |
| 4% | -54% |
| 5% | -54% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ABT, try ESMC, HOLX, BHC, CNMD, and IONS.
Loading social stream, please wait...